Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms

Franco Grimaldi, N Fazio, Roberto Attanasio, A Frasoldati, Enrico Papini, Nadia Cremonini, MV Davì, L Funicelli, S Massironi, F Spada, V Toscano, A Versari, M Zini, M Falconi, K Öberg

Research output: Contribution to journalArticle

Abstract

Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. © 2018 Bentham Science Publishers.
Original languageEnglish
Pages (from-to)419-449
Number of pages31
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Volume18
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Neoplasms
Professional Competence
Medical Oncology
Patient Preference
Therapeutics
Disease Progression
Comorbidity
Costs and Cost Analysis
Recurrence
Endocrinologists
methylamphotericin B

Cite this

Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms. / Grimaldi, Franco; Fazio, N; Attanasio, Roberto; Frasoldati, A; Papini, Enrico; Cremonini, Nadia; Davì, MV; Funicelli, L; Massironi, S; Spada, F; Toscano, V; Versari, A; Zini, M; Falconi, M; Öberg, K.

In: Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 18, No. 5, 2018, p. 419-449.

Research output: Contribution to journalArticle

Grimaldi, F, Fazio, N, Attanasio, R, Frasoldati, A, Papini, E, Cremonini, N, Davì, MV, Funicelli, L, Massironi, S, Spada, F, Toscano, V, Versari, A, Zini, M, Falconi, M & Öberg, K 2018, 'Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms', Endocrine, Metabolic and Immune Disorders - Drug Targets, vol. 18, no. 5, pp. 419-449. https://doi.org/10.2174/1871530318666171213145803
Grimaldi, Franco ; Fazio, N ; Attanasio, Roberto ; Frasoldati, A ; Papini, Enrico ; Cremonini, Nadia ; Davì, MV ; Funicelli, L ; Massironi, S ; Spada, F ; Toscano, V ; Versari, A ; Zini, M ; Falconi, M ; Öberg, K. / Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms. In: Endocrine, Metabolic and Immune Disorders - Drug Targets. 2018 ; Vol. 18, No. 5. pp. 419-449.
@article{d15ad30d72064529b8a862eb42dc2c30,
title = "Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms",
abstract = "Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. {\circledC} 2018 Bentham Science Publishers.",
author = "Franco Grimaldi and N Fazio and Roberto Attanasio and A Frasoldati and Enrico Papini and Nadia Cremonini and MV Dav{\`i} and L Funicelli and S Massironi and F Spada and V Toscano and A Versari and M Zini and M Falconi and K {\"O}berg",
year = "2018",
doi = "10.2174/1871530318666171213145803",
language = "English",
volume = "18",
pages = "419--449",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms

AU - Grimaldi, Franco

AU - Fazio, N

AU - Attanasio, Roberto

AU - Frasoldati, A

AU - Papini, Enrico

AU - Cremonini, Nadia

AU - Davì, MV

AU - Funicelli, L

AU - Massironi, S

AU - Spada, F

AU - Toscano, V

AU - Versari, A

AU - Zini, M

AU - Falconi, M

AU - Öberg, K

PY - 2018

Y1 - 2018

N2 - Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. © 2018 Bentham Science Publishers.

AB - Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. © 2018 Bentham Science Publishers.

U2 - 10.2174/1871530318666171213145803

DO - 10.2174/1871530318666171213145803

M3 - Article

VL - 18

SP - 419

EP - 449

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 5

ER -